Few things caught my eye post Q1 results.
- Research coverage of 3B BlackBio, is it the first?
- This new slide in the investor deck. As someone who’s tracked this mgmt for several years and knows how conservative they are, it’s refreshing to see some of these datapoints.
- For a molecular diagnostic valuation comp, Molbio is targeting an IPO in FY25 at a 22k-24k crore valuation or 30x FY24 revenue (with much worse unit economics than 3BB) per media reports.
Disc. Not invested
| Subscribe To Our Free Newsletter |
